Additionally, in the age-stratified analysis (stratified by the mean age of controls), the modifying effects of NOXA and MCL1 variants on risk of oropharyngeal cancer associated with HPV16 seropositivity was more pronounced among younger subjects (aged ≤ 58 year) than among older subjects (aged > 58 year) (Table 6). This evidence concerns the gene MCL1 and oropharynx cancer.